/PRNewswire/ Kamari Pharma announced today the completion of an $8 million investment by the Chinese fund GIBF2, managed by Dr. Shuki Gleitman, Prof. Shlomo.
The Guangzhou Sino-Israel Bio-industry Investment Fund, headed by Israel's former chief scientist, has already closed $200 million for its second fund to finance clinical trials